Most common phase 2–related adverse events
Adverse event . | Group 1 (n = 23) . | Group 2 (n = 21) . | Group 3 (n = 24) . | Total (n = 68) . | ||||
---|---|---|---|---|---|---|---|---|
% . | Grade 3/4, % . | % . | Grade 3/4, % . | % . | Grade 3/4, % . | % . | Grade 3/4, % . | |
Fatigue | 26 | 0 | 48 | 0 | 50 | 0 | 41 | 0 |
Diarrhea | 22 | 0 | 48 | 0 | 54 | 0 | 41 | 0 |
Neutropenia | 22 | 13 | 33 | 14 | 38 | 25 | 31 | 18 |
Anemia | 17 | 4 | 29 | 5 | 33 | 13 | 27 | 7 |
Thrombocytopenia | 26 | 4 | 19 | 5 | 25 | 0 | 24 | 3 |
Hypertension | 0 | 0 | 43 | 14 | 29 | 4 | 24 | 6 |
Nausea | 4 | 0 | 43 | 0 | 17 | 4 | 21 | 2 |
AST level increased | 22 | 4 | 19 | 5 | 13 | 4 | 18 | 4 |
Headache | 4 | 0 | 33 | 0 | 13 | 0 | 16 | 0 |
Leukopenia | 4 | 0 | 24 | 14 | 8 | 8 | 12 | 7 |
Dizziness | 0 | 0 | 19 | 0 | 13 | 0 | 10 | 0 |
Frequent bowel movements | 0 | 0 | 14 | 0 | 17 | 0 | 10 | 0 |
Dysgeusia | 9 | 0 | 19 | 0 | 4 | 0 | 10 | 0 |
ALT level increased | 9 | 4 | 14 | 5 | 8 | 4 | 10 | 4 |
Dyspnea | 4 | 0 | 14 | 0 | 13 | 0 | 10 | 0 |
Pyrexia | 13 | 0 | 5 | 0 | 8 | 0 | 9 | 0 |
Blood alkaline phosphatase level increased | 9 | 0 | 14 | 5 | 4 | 0 | 9 | 2 |
Febrile neutropenia | 4 | 4 | 5 | 0 | 13 | 8 | 7 | 4 |
Upper abdominal pain | 0 | 0 | 5 | 0 | 17 | 4 | 7 | 2 |
Dyspepsia | 4 | 0 | 14 | 0 | 4 | 0 | 7 | 0 |
Increased appetite | 4 | 0 | 10 | 0 | 8 | 0 | 7 | 0 |
Vomiting | 0 | 0 | 10 | 0 | 8 | 4 | 6 | 2 |
Flatulence | 0 | 0 | 14 | 0 | 4 | 0 | 6 | 0 |
Cough | 9 | 0 | 5 | 0 | 4 | 0 | 6 | 0 |
Blood bilirubin level increased | 4 | 0 | 5 | 0 | 0 | 0 | 6 | 0 |
Adverse event . | Group 1 (n = 23) . | Group 2 (n = 21) . | Group 3 (n = 24) . | Total (n = 68) . | ||||
---|---|---|---|---|---|---|---|---|
% . | Grade 3/4, % . | % . | Grade 3/4, % . | % . | Grade 3/4, % . | % . | Grade 3/4, % . | |
Fatigue | 26 | 0 | 48 | 0 | 50 | 0 | 41 | 0 |
Diarrhea | 22 | 0 | 48 | 0 | 54 | 0 | 41 | 0 |
Neutropenia | 22 | 13 | 33 | 14 | 38 | 25 | 31 | 18 |
Anemia | 17 | 4 | 29 | 5 | 33 | 13 | 27 | 7 |
Thrombocytopenia | 26 | 4 | 19 | 5 | 25 | 0 | 24 | 3 |
Hypertension | 0 | 0 | 43 | 14 | 29 | 4 | 24 | 6 |
Nausea | 4 | 0 | 43 | 0 | 17 | 4 | 21 | 2 |
AST level increased | 22 | 4 | 19 | 5 | 13 | 4 | 18 | 4 |
Headache | 4 | 0 | 33 | 0 | 13 | 0 | 16 | 0 |
Leukopenia | 4 | 0 | 24 | 14 | 8 | 8 | 12 | 7 |
Dizziness | 0 | 0 | 19 | 0 | 13 | 0 | 10 | 0 |
Frequent bowel movements | 0 | 0 | 14 | 0 | 17 | 0 | 10 | 0 |
Dysgeusia | 9 | 0 | 19 | 0 | 4 | 0 | 10 | 0 |
ALT level increased | 9 | 4 | 14 | 5 | 8 | 4 | 10 | 4 |
Dyspnea | 4 | 0 | 14 | 0 | 13 | 0 | 10 | 0 |
Pyrexia | 13 | 0 | 5 | 0 | 8 | 0 | 9 | 0 |
Blood alkaline phosphatase level increased | 9 | 0 | 14 | 5 | 4 | 0 | 9 | 2 |
Febrile neutropenia | 4 | 4 | 5 | 0 | 13 | 8 | 7 | 4 |
Upper abdominal pain | 0 | 0 | 5 | 0 | 17 | 4 | 7 | 2 |
Dyspepsia | 4 | 0 | 14 | 0 | 4 | 0 | 7 | 0 |
Increased appetite | 4 | 0 | 10 | 0 | 8 | 0 | 7 | 0 |
Vomiting | 0 | 0 | 10 | 0 | 8 | 4 | 6 | 2 |
Flatulence | 0 | 0 | 14 | 0 | 4 | 0 | 6 | 0 |
Cough | 9 | 0 | 5 | 0 | 4 | 0 | 6 | 0 |
Blood bilirubin level increased | 4 | 0 | 5 | 0 | 0 | 0 | 6 | 0 |